BETA

34 Amendments of Cristian-Silviu BUŞOI related to 2014/0257(COD)

Amendment 156 #
Proposal for a regulation
Recital 37 a (new)
(37a) As Antimicrobial resistance to human and veterinary medicinal products is a growing health problem in the Union and worldwide there must soon also action be taken in the field of human medicine for example in the form of an instrument incentivising the development of new antibiotics for human use similar to that already proposed within this regulation.
2015/06/17
Committee: ENVI
Amendment 248 #
Proposal for a regulation
Article 4 – paragraph 1 – point 20 – point b a (new)
(ba) veterinary medicinal products for animal species the national population of which is not large enough for research and development costs to be amortised during the data protection period specified in Article 34.
2015/06/17
Committee: ENVI
Amendment 358 #
Proposal for a regulation
Article 21 – paragraph 2
2. By way of derogation from Article 5(2), a marketing authorisation for a limited market shall be granted for a period of 3 years. At the end of that period, the holder may request, in the light of scientific data and on grounds of pharmacovigilance and efficiency, that this authorisation be converted into an open-ended authorisation.
2015/06/17
Committee: ENVI
Amendment 369 #
Proposal for a regulation
Article 22 – paragraph 1 – point c
(c) a requirement to conduct post- authorisation studiessupply post- authorisation data based on post- authorisation studies identified as necessary on the basis of changes in the benefit-risk balance and on data gathered from the product’s use in the field.
2015/06/17
Committee: ENVI
Amendment 438 #
Proposal for a regulation
Article 34 – paragraph 1 – point a
(a) 10 years for the veterinary medicinal products for cattle, sheep, pigs, chickens, dogs and cats;
2015/06/17
Committee: ENVI
Amendment 440 #
Proposal for a regulation
Article 34 – paragraph 1 – point b
(b) 14 years for antimicrobial veterinary medicinal products for cattle, sheep, pigs, chickens, dogs and cats containing an antimicrobial active substance which has not been an active substance in a veterinary medicinal product authorised within the Union on the date of the submission of the application;
2015/06/17
Committee: ENVI
Amendment 448 #
Proposal for a regulation
Article 35 – paragraph 1
1. Where a variation is approved in accordance with Article 65 extending the marketing authorisation to another species listed in Article 34(1)(a), the period of the protection provided for in that Article shall be prolonged by 1two years for each additional target species, provided that the variation has been submitted at least 34 years before the expiration of the protection period laid down in Article 341(1)(a).
2015/06/17
Committee: ENVI
Amendment 519 #
Proposal for a regulation
Article 68 – paragraph 1
1. A harmonised summary of product characteristics shall be prepared in accordance with the procedure laid down in Article 69 for groups of similar veterinary medicinal products, other than homeopathic veterinary medicinal products, which have the same qualitative and quantitative composition of their active substances and the same pharmaceutical form and have been shown to be bio-equivalents, for which national marketing authorisations have been granted in different Member States before 1 January 2004the entry into force of this new Regulation and for which summaries of product characteristics approved at national level demonstrate a proven difference (‘similar products’).
2015/06/17
Committee: ENVI
Amendment 521 #
Proposal for a regulation
Article 68 – paragraph 2 a (new)
2a. Marketing authorisation holders may, pursuant to Article 69, request a harmonisation of the various national marketing authorisations granted for the same veterinary medicinal product.
2015/06/17
Committee: ENVI
Amendment 522 #
Proposal for a regulation
Article 68 – paragraph 2 b (new)
2b. A single set of quality data and a harmonised summary of product characteristics shall be prepared for veterinary medicinal products, other than homeopathic veterinary medicinal products, which have the same qualitative and quantitative composition of their active substances and the same pharmaceutical form and marketing authorisation holder, and for which national marketing authorisations have been granted in different Member States (‘same products’). The coordination group shall establish procedural rules for the harmonisation of ‘same products’.
2015/06/17
Committee: ENVI
Amendment 523 #
Proposal for a regulation
Article 68 – paragraph 2 c (new)
2c. National marketing authorisations may be harmonised with decentralised marketing authorisations and/or mutual recognition marketing authorisations if they are for the same product.
2015/06/17
Committee: ENVI
Amendment 535 #
Proposal for a regulation
Article 69 – paragraph 3
3. Within 120 days of his appointment, the rapporteur shall present to the coordination group a report regarding possible harmonisation of summaries of product characteristics for the similar veterinary medicinal products in the group and propose a harmonised summary of products characteristicwith a proposal for harmonisation of the conditions for use of the group of essentially similar veterinary medicinal products or for marketing authorisation for same veterinary medicinal products.
2015/06/17
Committee: ENVI
Amendment 538 #
Proposal for a regulation
Article 69 – paragraph 4 – introductory part
4. Harmonised summaries of product characteristics for veterinary medicinal productsconditions of use shall contain all oft least the following information:
2015/06/17
Committee: ENVI
Amendment 540 #
Proposal for a regulation
Article 69 – paragraph 4 – point a
(a) all species mentioned in the marketing authorisations granted by Member States in respect of the essentially similar products in the group;
2015/06/17
Committee: ENVI
Amendment 543 #
Proposal for a regulation
Article 69 – paragraph 4 – point b
(b) all therapeutic indications and dosages mentioned in the marketing authorisations granted by Member States in respect of the essentially similar products in the group, except for indications regarding the prophylactic use of antimicrobials;
2015/06/17
Committee: ENVI
Amendment 545 #
Proposal for a regulation
Article 69 – paragraph 4 – point c
(c) the shortesta withdrawal period of those stated in the summaries of the product characteristicswhich ensures that consumers are adequately protected.
2015/06/17
Committee: ENVI
Amendment 552 #
Proposal for a regulation
Article 69 – paragraph 6
6. In the event of an opinion in favour of adopting a harmonised summary of the product characteation of conditions of use or of a harmonisation of a marketing authorisaticson, each Member State shall vary athe marketing authorisation in conformity with the agreement within 30 days of receipt of the information regarding the agreement from the rapporteurs of the products in their territory so that the elements listed in paragraph 4, where they are already included in the summaries of characteristics for a product belonging to that group, are in conformity with the agreement within 30 days of receipt of the information regarding the agreement from the rapporteur. Those marketing authorisations shall now be considered as mutually recognised marketing authorisations granted by virtue of this Regulation.
2015/06/17
Committee: ENVI
Amendment 560 #
Proposal for a regulation
Article 71 – paragraph 1
Upon request from the coordination group or the Agency, holders of the marketing authorisations for products included in a group of essentially similar products identified for a harmonisation of the summaries of the product characteristics shall submit information concerning their products, or individual holders of marketing authorisations for the same product identified for harmonisation of marketing authorisations shall submit information concerning their products, including a proposal for the harmonisation of the summaries of the product characteristics for their medicines belonging to that group.
2015/06/17
Committee: ENVI
Amendment 659 #
Proposal for a regulation
Article 83 – paragraph 4
4. The competent authority or the Commission may at any time grant a marketing authorisation valid for an unlimited period of time, provided that the marketing authorisation holder submits the missing comprehensive safety and efficacy data refissing key studies have been submitted by the marketing authorisation holder and that no safety issues or absence of effectiveness have been obserrved to in Article 22(1)during field usage.
2015/06/17
Committee: ENVI
Amendment 732 #
Proposal for a regulation
Article 109 – title
Retail ofnly of medicinal products which are subject to prescription, or active substances, with anabolic, anti-infectious, anti- parasitic, anti-inflammatory, hormonal or psychotropic veterinary medicinal productproperties
2015/06/17
Committee: ENVI
Amendment 738 #
Proposal for a regulation
Article 109 – paragraph 1
1. Only manufacturers, wholesale distributors and retailers authorised specifically to do so in accordance with applicable national law shall be allowed to supply and purchase prescription veterinary medicinal products which have anabolic, anti- infectious, anti-parasitic, anti- inflammatory, hormonal or psychotropic properties or substances which may be used as veterinary medicinal products having those properties.
2015/06/17
Committee: ENVI
Amendment 743 #
Proposal for a regulation
Article 109 – paragraph 3 – subparagraph 1 – introductory part
Those manufacturers and suppliers shall keep detailed records of the following information in respect of each purchase and sale transaction pertaining to prescription veterinary medicinal products:
2015/06/17
Committee: ENVI
Amendment 900 #
Proposal for a regulation
Article 125 – paragraph 1 a (new)
1a. To combat fraud, the competent authorities shall establish a plan for spot checks on veterinary practices and herds to verify that medicinal products held comply with quality standards, in order to combat fraud.
2015/06/17
Committee: ENVI
Amendment 906 #
Proposal for a regulation
Article 129 – paragraph 4
4. Where necessary for reasons of human or animal health, a competent authority may require the marketing authorisation holder for an immunological veterinary medicinal product to submit samples of batches of the bulk product and/or veterinary medicinal product for control by an Official Medicines Control Laboratory before the product is made available on the market.deleted
2015/06/17
Committee: ENVI
Amendment 907 #
Proposal for a regulation
Article 129 – paragraph 5 – subparagraph 1
Upon request by the competent authority, the marketing authorisation holder shall promptly supply the samples referred to in paragraph 4, together with the reports of the control referred to in this Chapter. The competent authority shall inform the competent authorities in other Member States in which the veterinary medicinal product is authorised as well as the European Directorate for the Quality of Medicines & HealthCare of its intention to control batches or the batch in question.deleted
2015/06/17
Committee: ENVI
Amendment 908 #
Proposal for a regulation
Article 129 – paragraph 5 – subparagraph 2
In such cases, the competent authorities of another Member State shall not apply the provisions of paragraph 4.deleted
2015/06/17
Committee: ENVI
Amendment 909 #
Proposal for a regulation
Article 129 – paragraph 6
6. On the basis of the control reports referred to in this Chapter, the laboratory responsible for the control shall repeat, on the samples provided, all the tests carried out by the manufacturer on the finished product, in accordance with the relevant provisions shown in the dossier for marketing authorisation.deleted
2015/06/17
Committee: ENVI
Amendment 910 #
Proposal for a regulation
Article 129 – paragraph 7
7. The list of tests to be repeated by the laboratory responsible for the control shall be restricted to justified tests, provided that all competent authorities in the Member States concerned, and if appropriate the European Directorate for the Quality of Medicines & HealthCare, agree to this. For immunological veterinary medicinal products authorised under the centralised procedure, the list of tests to be repeated by the control laboratory may be reduced only upon agreement of the Agency.deleted
2015/06/17
Committee: ENVI
Amendment 911 #
Proposal for a regulation
Article 129 – paragraph 7 – subparagraph 1
The list of tests to be repeated by the laboratory responsible for the control shall be restricted to justified tests, provided that all competent authorities in the Member States concerned, and if appropriate the European Directorate for the Quality of Medicines & HealthCare, agree to this.deleted
2015/06/17
Committee: ENVI
Amendment 912 #
Proposal for a regulation
Article 129 – paragraph 7 – subparagraph 2
For immunological veterinary medicinal products authorised under the centralised procedure, the list of tests to be repeated by the control laboratory may be reduced only upon agreement of the Agency.deleted
2015/06/17
Committee: ENVI
Amendment 913 #
Proposal for a regulation
Article 129 – paragraph 8
8. The competent authorities shall recognise the results of the tests.deleted
2015/06/17
Committee: ENVI
Amendment 914 #
Proposal for a regulation
Article 129 – paragraph 9
9. Unless the Commission is informed that a longer period is necessary to conduct the tests, the competent authorities shall ensure that this control is completed within 60 days of receipt of the samples.deleted
2015/06/17
Committee: ENVI
Amendment 915 #
Proposal for a regulation
Article 129 – paragraph 10
10. The competent authority shall notify the competent authorities of other Member States concerned, the European Directorate for the Quality of Medicines & HealthCare, the marketing authorisation holder and, if appropriate, the manufacturer, of the results of the tests within the same period of time.deleted
2015/06/17
Committee: ENVI
Amendment 916 #
Proposal for a regulation
Article 129 – paragraph 11
11. If a competent authority concludes that a batch of a veterinary medicinal product is not in conformity with the control report of the manufacturer or the specifications provided for in the marketing authorisation, it shall take measures vis-a-vis the marketing authorisation holder and the manufacturer, and shall inform accordingly the competent authorities of other Member States in which the veterinary medicinal product is authorised.deleted
2015/06/17
Committee: ENVI